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Objectives: Previous studies have found that recurrent or per-
istent co-infectionsmay increase HIV viral load (VL) in plasma and
enital secretions. This elevation in HIV VL may increase the risk of
IV transmission, thus increasing HIV incidence. We evaluated the
ssociation between malaria, herpes simplex type 2 (HSV-2) and
uberculosis (TB) co-infections and their treatment on HIV VL.
Design: Systematic review and meta-analysis of the association
f malaria, HSV-2 and TB co-infections and their treatment on HIV
L.
Methods: PubMed and Embase databases were searched to
ebruary 10th 2010 for studies in adults that reported HIV plasma
nd/or genital VL by co-infection status or treatment. Studies that
djusted for CD4 count or time since infectionwere included.Meta-
nalyses were conducted using random-effects models.
Results: Forty-ﬁveeligible articleswere identiﬁed (6malaria, 20
SV-2 and19 tuberculosis). Therewas strong evidence of increased
IVVLwith acutemalaria (0.67 log10 copies/mL, 95%CI: 0.15, 1.19)
nd decreased VL following treatment (-0.37 log10 copies/mL, 95%
I: -0.70, -0.04). HSV-2 infectionwas also associatedwith increased
IV VL (0.18 log10 copies/mL, 95% CI: 0.01, 0.34), which decreased
ithHSVsuppressive therapy (-0.28 log10copies/mL, 95%CI: -0.36,
0.19). Active tuberculosis was associated with increased HIV VL
log10 copies/mL 0.40, 95% CI: 0.13-0.67), but there was no asso-
iation between tuberculosis treatment and VL reduction (log10
opies/mL -0.02, 95% CI -0.19, 0.15).
Conclusions: Co-infections may increase HIV VL in populations
here they are prevalent, thereby facilitating HIV transmission.
reatment or co-infection prophylaxis could reverse the effect of
o-infections. However, to limit HIV trajectory and optimize pos-
tive prevention for HIV-infected individuals pre-ART, we must
etter understand the mechanisms responsible for augmented VL
nd the magnitude of VL reduction required, and retune treatment
egimens accordingly.
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Background: Coinfection with human immunodeﬁciency virus
(HIV) and hepatitis B (HBV) is a growing public concern, espe-
cially in Asia and Africa where both HIV and HBV are epidemic.
The progression of chronic HBV to cirrhosis, end-stage liver disease
and hepatocellular carcinoma is more rapid in HIV-infected per-
sons than in persons with chronic HBV alone. Conversely, chronic
HBV does not substantially alter the HIV disease progression and
does not inﬂuence on CD4/HIV RNA response to ART. However,
ARV related hepatotoxicity, hepatic ﬂare due to immune recovery
syndrome after initiating ART, lamivudine resistant, or HBV drug
discontinuation can be associated with elevation in transaminases.
First line treatment for chronic HBV mono infection is pegylated
Interferon, tenofovir or entecavir. Since, lamivudine resistant is
observed in 20-25% per year, therefore, lamivudine/emtricitabine
should not be used as a mono HBV drug. Due to faster liver dis-
ease progression in HIV-HBV co-infection, ARV treatment should
be initiated early. Combination of tenofovir plus emtricitabine or
lamivudne as NRTI backbone is recommended for all HIV-HBV
infected individuals in need for ART treatment. If HBV need treat-
ment but HIV treatment is not indicated (CD4> 500 cells/mm3),
HBVdrugwithoutHIVactivity ie1)pegylated interferon for selected
population (lowHBVDNA, genotypeA, absent cirrhosis); 2) telbivu-
dine/adefovir or 3) early ART is suggested. For HIV-HBV patients
with renal problem and tenofovir could not be safety used, there is
currently no solid evidence to suggest the best strategy. The alter-
nativeoptionwouldbe1)entecavir inaddition toa fully suppressive
ART regimen, 2) pegylated interferon monotherapy, 3) adefovir
plus emtricitabine or lamivudine, or 4) telbivudine in addition to a
fully suppressive ART regimen. If ART needs to be modiﬁed due to
HIV virological failure and patient has adequate HBV suppression,
tenofovir and/or emtricitabine (or lamivudine) should be contin-
ued for HBV treatment in addition to other active ART regimen.
Finally, primary prevention for HBV infection and screening for
hepatocellular carcinoma is warranted.
Conclusion: This presentation will focus on the important of
HBV and treatment strategy in HIV-HBV infected individual. In
addition, HBV vaccine and primary prevention for hepatocellular
carcinoma are also addressed.
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